scholarly journals O12‐1: Pulmonary hyperinflation and the risk of COPD exacerbation: Analysis from KOCOSS cohort

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 32-32
Keyword(s):  
Copd Exacerbation ◽  
Pulmonary Hyperinflation

Serum Magnesium Levels in Exacerbation of COPD: A Single Centre Prospective Study from Kashmir, India.

JMS SKIMS ◽  
2010 ◽  
Vol 13 (1) ◽  
pp. 15-19
Author(s):  
Bashir Ahmed Shah ◽  
Muzafar Ahmed Naik ◽  
Sajjad Rajab ◽  
Syed Muddasar ◽  
Ghulam Nabi Dhobi ◽  
...  
Keyword(s):  
Acute Exacerbation ◽  
Serum Magnesium ◽  
Stage Iii ◽  
Advanced Stage ◽  
Copd Exacerbation ◽  
Post Discharge ◽  
Duration Of Symptoms ◽  
Copd Patients ◽  
Exacerbation Of Copd ◽  
Time Of Admission

Objective: To study the significance of serum magnesium levels during COPD exacerbation and stability.Materials & Methods: The patient population consisted of all patients of COPD admitted as acute exacerbation as defined by the Anthonisens criteria, from June 2006 to may 2008. Same patients one month post discharge presenting to the OPD for routine check up as stable COPD served as controls. Results: A total number of 77 patients of COPD presenting as acute exacerbation were included in the study. The incidence of Hypomagnesaemia was 33.8% at admission; 5% at discharge and 4% at one month of post discharge in COPD patients. The mean serum magnesium levels were significantly lower in cases than controls (1.88±0.67mg/ dl V/S 2.3±0.36mg/dl; p<0.0001). Also, hypomagnesemia was present in higher number of cases (22/77, 33.8%) compared to controls, 3/75, 4.0%; (p<0.0001). Patients of COPD with acute exacerbation and hypomagnesemia, had longer duration of symptoms and had advanced stage III of COPD (p<0.001); and had raised mean corpuscle volume (p<0.045) and longer hospital stay (p<0.008).  Conclusion: We conclude COPD exacerbation is associated with hypomagnesemia. The duration of symptoms of more than 8 days, advanced stage of COPD (stage III) and raised MCV were associated with hypomagnesemia. We recommend to monitor serum magnesium levels in COPD patients with acute exacerbation at the time of admission and during their stay in the hospital.J Med Sci.2010;13(1);15-19

COPD Exacerbation Re-Admission Rates In Active And Ex-Tobacco Smokers

2012 ◽  
Author(s):  
Andrew Singer ◽  
Janet Williams ◽  
Nicola Garner ◽  
Tracy Monaghan ◽  
Katya Lyulcheva-Bennett ◽  
...  
Keyword(s):  
Copd Exacerbation ◽  
Admission Rates

Anemia is a Mortality Predictor in Hospitalized Patients for COPD Exacerbation

2012 ◽  
Vol 9 (3) ◽  
pp. 243-250 ◽  
Author(s):  
Carlos Martinez-Rivera ◽  
Karina Portillo ◽  
Aida Muñoz-Ferrer ◽  
María Luisa Martínez-Ortiz ◽  
Elena Molins ◽  
...  
Keyword(s):  
Hospitalized Patients ◽  
Copd Exacerbation

scholarly journals Use of a SmartPhone/Tablet-Based Bidirectional Telemedicine Disease Management Program Facilitates Early Detection and Treatment of COPD Exacerbation Symptoms

2016 ◽  
Vol 22 (5) ◽  
pp. 395-399 ◽  
Author(s):  
Heidi S. Smith ◽  
Andrew J. Criner ◽  
Dolores Fehrle ◽  
Carla L. Grabianowski ◽  
Michael R. Jacobs ◽  
...  
Keyword(s):  
Disease Management ◽  
Early Detection ◽  
Disease Management Program ◽  
Management Program ◽  
Copd Exacerbation

Outcomes of Peripheral Blood Eosinophilia in Hospitalized Exacerbations of COPD

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Samar El Sharkawy ◽  
Riham Hazem Raafat ◽  
Reem Osama Mohamed Ahmed Qassem
Keyword(s):  
Peripheral Blood ◽  
Diagnostic Performance ◽  
Leukocyte Count ◽  
Airflow Limitation ◽  
Total Leukocyte Count ◽  
Blood Eosinophil ◽  
Copd Exacerbation ◽  
Peripheral Blood Eosinophil ◽  
Copd Exacerbations ◽  
Cutoff Points

Abstract Background The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines define COPD as a disease state characterized by airflow limitation that is not fully reversible, is usually progressive, and is associated with an abnormal inflammatory response of the lungs to inhaled noxious particles or gases. Objective To identify outcomes of patients with eosinophilic COPD exacerbations requiring hospital admission. Patients and Methods This study is a prospective cohort study that was conducted on two groups of total 60 patients recruited from Ain Shams University hospitals between October 2019 and July 2020. Group 1: Eosinophilic COPD exacerbation if the peripheral blood eosinophil on admission is ≥ 200 cells/µL and/or ≥2% of the total leukocyte count Group 2: Non-eosinophilic COPD exacerbation if the peripheral blood eosinophil on admission is &lt; 200 cells/µL and/or &lt; 2% of the total leukocyte count. Results There was significant high diagnostic performance in predicting readmission at 6-month among eosinophilic group. Eosinophils count, percent (%) and NLR cutoff points had high characteristics (highest in NLR ≥3.1 at discharge) in predicting readmission at 6-month among eosinophilic group. Diagnostic performance of Eosinophils count, percent (%) and NLR were assessed. Eosinophils count, percent (%) and NLR had significant high diagnostic performance in predicting readmission at 6-month among eosinophilic group. Eosinophils count, % and NLR cutoff points had high characteristics (highest in NLR ≥2.1 at discharge) in predicting readmission at 6month among non-eosinophilic group. Conclusion Eosinophils can be used as a prognostic marker in non-infective COPD exacerbations. Validity of eosinophil count and percent as a prognostic parameter in COPD exacerbation can be increased by combining with other parameters for example NLR.

Sign in / Sign up

Export Citation Format

Share Document